These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 36387152)

  • 1. A composite indicator of derived neutrophil-lymphocyte ratio and lactate dehydrogenase correlates with outcomes in pancreatic carcinoma patients treated with PD-1 inhibitors.
    Chen S; Guo S; Gou M; Pan Y; Fan M; Zhang N; Tan Z; Dai G
    Front Oncol; 2022; 12():951985. PubMed ID: 36387152
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic Value of the Pretreatment Lung Immune Prognostic Index in Advanced Small Cell Lung Cancer Patients Treated With First-Line PD-1/PD-L1 Inhibitors Plus Chemotherapy.
    Li L; Pi C; Yan X; Lu J; Yang X; Wang C; Li X; Zhang S; Zhang Z; Sun Y; Hu Y
    Front Oncol; 2021; 11():697865. PubMed ID: 34692478
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Composite Biomarker of Derived Neutrophil-Lymphocyte Ratio and Platelet-Lymphocyte Ratio Correlates With Outcomes in Advanced Gastric Cancer Patients Treated With Anti-PD-1 Antibodies.
    Pan Y; Si H; Deng G; Chen S; Zhang N; Zhou Q; Wang Z; Dai G
    Front Oncol; 2021; 11():798415. PubMed ID: 35251952
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Predictive Value of Pretreatment Lactate Dehydrogenase and Derived Neutrophil-to-Lymphocyte Ratio in Advanced Non-Small Cell Lung Cancer Patients Treated With PD-1/PD-L1 Inhibitors: A Meta-Analysis.
    Zhang Q; Gong X; Sun L; Miao L; Zhou Y
    Front Oncol; 2022; 12():791496. PubMed ID: 35924149
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non-Small Cell Lung Cancer.
    Mezquita L; Auclin E; Ferrara R; Charrier M; Remon J; Planchard D; Ponce S; Ares LP; Leroy L; Audigier-Valette C; Felip E; Zerón-Medina J; Garrido P; Brosseau S; Zalcman G; Mazieres J; Caramela C; Lahmar J; Adam J; Chaput N; Soria JC; Besse B
    JAMA Oncol; 2018 Mar; 4(3):351-357. PubMed ID: 29327044
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of the Pretreatment Lung Immune Prognostic Index with Survival Outcomes in Advanced Hepatocellular Carcinoma Patients Treated with PD-1 Inhibitors.
    Chen S; Huang Z; Jia W; Tao H; Zhang S; Ma J; Liu Z; Wang J; Wang L; Cui P; Zhang Z; Huang D; Wu Z; Zheng X; Hu Y
    J Hepatocell Carcinoma; 2020; 7():289-299. PubMed ID: 33173757
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Prognostic Value of Gastric Immune Prognostic Index in Gastric Cancer Patients Treated With PD-1/PD-L1 Inhibitors.
    Chen L; Zhao R; Sun H; Huang R; Pan H; Zuo Y; Zhang L; Xue Y; Li X; Song H
    Front Pharmacol; 2022; 13():833584. PubMed ID: 35795575
    [No Abstract]   [Full Text] [Related]  

  • 8. Clinical Significance of Serum Biomarkers in Stage IV Non-Small-Cell Lung Cancer Treated with PD-1 Inhibitors: LIPI Score, NLR, dNLR, LMR, and PAB.
    Chen J; Wei S; Zhao T; Zhang X; Wang Y; Zhang X
    Dis Markers; 2022; 2022():7137357. PubMed ID: 35945957
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predicting Immunotherapy Outcomes in Older Patients with Solid Tumors Using the LIPI Score.
    Pierro M; Baldini C; Auclin E; Vincent H; Varga A; Martin Romano P; Vuagnat P; Besse B; Planchard D; Hollebecque A; Champiat S; Marabelle A; Michot JM; Massard C; Mezquita L
    Cancers (Basel); 2022 Oct; 14(20):. PubMed ID: 36291861
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High score of LDH plus dNLR predicts poor survival in patients with HER2-positive advanced breast cancer treated with trastuzumab emtansine.
    Li L; Ai L; Jia L; Zhang L; Lei B; Zhang Q
    BMC Cancer; 2022 Jan; 22(1):29. PubMed ID: 34980025
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab.
    Capone M; Giannarelli D; Mallardo D; Madonna G; Festino L; Grimaldi AM; Vanella V; Simeone E; Paone M; Palmieri G; Cavalcanti E; Caracò C; Ascierto PA
    J Immunother Cancer; 2018 Jul; 6(1):74. PubMed ID: 30012216
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic value of an inflammatory index for patients with metastatic castration-resistant prostate cancer.
    Yamada Y; Sakamoto S; Rii J; Yamamoto S; Kamada S; Imamura Y; Nakamura K; Komiya A; Nakatsu H; Ichikawa T
    Prostate; 2020 May; 80(7):559-569. PubMed ID: 32134137
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic Value of the Lung Immune Prognostic Index for Patients Treated for Metastatic Non-Small Cell Lung Cancer.
    Kazandjian D; Gong Y; Keegan P; Pazdur R; Blumenthal GM
    JAMA Oncol; 2019 Oct; 5(10):1481-1485. PubMed ID: 31343662
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of a Systemic Inflammatory Biomarker in Advanced Bile Tract Carcinoma Treated with Anti-PD-1 Therapy: Prognostic and Predictive Significance of Lung Immune Prognostic Index Score.
    Pan Y; Si H; Jia R; Deng G; Yan H; Fan M; Gou M; Chen S; Zhang N; Shi Y; Qian N; Dai G
    J Oncol; 2022; 2022():1427779. PubMed ID: 35342416
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pretreatment Blood Parameters Predict Efficacy from Immunotherapy Agents in Early Phase Clinical Trials.
    Criscitiello C; Marra A; Morganti S; Zagami P; Viale G; Esposito A; Curigliano G
    Oncologist; 2020 Nov; 25(11):e1732-e1742. PubMed ID: 32785940
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of the pretreatment lung immune prognostic index with immune checkpoint inhibitor outcomes in patients with advanced hepatocellular carcinoma.
    Sun T; Guo Y; Sun B; Chen L; Ren Y; Zhu L; Zhang L; Liu Y; Zheng C
    Eur J Med Res; 2023 Jul; 28(1):225. PubMed ID: 37408056
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The prognostic value of the derived neutrophil-to-lymphocyte ratio (dNLR) in patients treated with immune checkpoint inhibitors.
    Mullally WJ; Greene J; Jordan EJ; Horgan AM; O'Connor M; Calvert PM
    Ir J Med Sci; 2023 Feb; 192(1):83-87. PubMed ID: 35304710
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The novel pretreatment immune prognostic index discriminates survival outcomes in locally advanced non-operative esophageal squamous cell carcinoma patients treated with definitive chemoradiotherapy: a 6-year retrospective study.
    Yu Y; Wu H; Qiu J; Ke D; Wu Y; Lin M; Zheng Q; Zheng H; Wang Z; Li H; Liu L; Li J; Yao Q
    Transl Oncol; 2022 Jul; 21():101430. PubMed ID: 35452997
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Determinants of survival in advanced non-small cell lung cancer patients treated with anti-PD-1/PD-L1 therapy.
    Ali WAS; Hui P; Ma Y; Wu Y; Zhang Y; Chen Y; Hong S; Yang Y; Huang Y; Zhao Y; Fang W; Zhao H; Zhang L
    Ann Transl Med; 2021 Nov; 9(22):1639. PubMed ID: 34988148
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic value of derived neutrophil-to-lymphocyte ratio (dNLR) in patients with non-small cell lung cancer receiving immune checkpoint inhibitors: a meta-analysis.
    Yang T; Hao L; Yang X; Luo C; Wang G; Lin Cai C; Qi S; Li Z
    BMJ Open; 2021 Sep; 11(9):e049123. PubMed ID: 34475167
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.